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Abstract
Background: Epithelial-to-mesenchymal transition (EMT) is a morphologic transdifferentiation of carcinomas, conferring increased tumour
invasiveness, but may also be applied to the epithelioid versus sarcomatoid histotype of malignant pleural mesothelioma (MPM). Herein, we
correlated proteins of a putative MPM—EMT axis, including periostin, epidermal growth factor receptor (EGFR), integrin b1, phosphatase and
tensin homologue (PTEN), integrin-linked kinase (ILK), p21 and p27, with clinico-pathologic parameters, in particular overall survival (OS).
Patients and Methods: A retrospective cohort of 352 mostly untreated patients with MPM was investigated by immunohistochemistry of a tissue
microarray. Protein expression intensities were semi-quantitatively scored from 0 to 3 in their respective compartments, including peritumoural
stroma as well as tumour cell plasma membrane, cytoplasm or nucleus. Data were correlated with histotype and survival outcome. Results: A
total of 32% of the tumours were diagnosed as epithelioid, 13% as sarcomatoid and 55% as biphasic histotype. High expression ofmembranous EGFR
and integrin b1 as well as nuclear p27 correlated with the epithelioid and high expression of cytoplasmic tumoural and stromal periostin with the
sarcomatoid histotype. The median survival time of the 128 patients with complete follow-up data was 11.7 months. Univariate survival analysis
revealed age, epithelioid histotype and any therapy as prognosticators for better OS. High expression of cytoplasmic PTEN or ILK as well as high
expression of nuclear p21 or p27 correlated with increased, whereas high expression of cytoplasmic periostin with decreased OS (all p values
<0.05). Multivariate Cox regression revealed any treatment, low cytoplasmic periostin and high cytoplasmic PTEN as independent prognos-
ticators for better OS. Conclusion: Activation of periostin-triggered EMT is associated with the sarcomatoid histotype and has an impact on
shorter survival of MPM patients. Finally, only the high expression of PTEN and the low expression of cytosolic periostin could be shown to be
independent prognostic factors for longer OS.
# 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
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Despite multimodality treatment including neo-adjuvant
chemotherapy, radical surgery and adjuvant radiotherapy,
the prognosis of malignant pleural mesothelioma (MPM) is
still limited. The aggressiveness of this tumour maybe
explained by its partial fibroblastic phenotype in the context
of epithelial-to-mesenchymal transition (EMT), conferring
both high invasiveness and chemoresistance.
EMT is a developmental programme of foetal and tumoural
cells, characterised by loss of cell adhesion, repression of E-
cadherin expression and increased cell motility [1]. Con-§ Presented at the 17th European Conference on General Thoracic Surgery,
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nents and manifest a migratory phenotype. As tumours often
mimic embryonic development, it is postulated that EMT is an
important probably transient, event in the progression,
invasion and metastasis of carcinomas and it may be a
permanent feature in sarcomatoid carcinomas, which have a
particularly dismal prognosis [2]. The inverse process is
called mesenchymal—epithelial transition (MET) [3]. Apart
from sarcomatoid carcinoma, which is rare in most organs,
one might assume MPM to potentially be one of the best in
vivo models for EMT—MET transdifferentiation, since it
consists of two distinct histotypes — epithelioid and
sarcomatoid — and the additional biphasic one may be
considered a true intermediate, assembling cells with either
of the two differentiations in close proximity. Importantly,
mesothelial cells are of coelomic and therefore mesodermal
origin, and thus may be viewed as cells having undergone at
least partial EMT during embryogenesis.urgery. Published by Elsevier B.V. All rights reserved.
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expression, distribution and/or function of proteins that
include extracellular matrix and plasma membrane proteins
such as periostin, vimentin, integrins, matrix metalloprotei-
nases (MMPs) and cadherins [2,4]. With regard to signalling,
several oncogenic pathways such as peptide growth factors,
Src, Ras, Ets, Wnt/beta-catenin and Notch, can induce EMT
[5]. Activation of the phosphatidylinositol-3 kinase (PI3K)/
Akt axis seems to be a central feature of EMT, and this
activation can be abolished by PTEN [6,7].
In the previous studies, we have demonstrated that
cytosolic loss of PTEN is associated with decreased overall
survival of MPM patients [8]. Furthermore, we have found the
extracellular matrix protein periostin to be involved in EMTof
non-small-cell lung cancer (NSCLC), whereby high stromal
expression, in particular, was associated with decreased
progression-free and overall survival [9].
In this study, we analysed the protein expression of
individual members of a complete putative MPM—EMT
signalling cascade, including the extracellular matrix and
cell adhesion protein periostin, the two cross-talking plasma
membrane receptors EGFR and integrin b1, the two
associated adaptor and regulator proteins PTEN and ILK
and the two downstream effectors of the Akt pathway, p21
and p27, in a larger, mostly untreated cohort of MPM (n = 352)
by immunohistochemistry. We tested the null hypothesis that
individual protein expression levels do not correlate with
each other, or with clinico-pathologic parameters including
histotype and OS.
2. Patients and methods
2.1. Patients and histological subtypes
Tissue specimens of 352 patients with MPMs, diagnosed
between 1975 and 2004, were sent to the Zu¨rich Pneumo-
coniosis research group for mineralogical assessment of dust
exposure, in particular, asbestos, and later included in this
study. The total cohort comprised 114 epithelioid, 192
biphasic and 46 sarcomatoid histotypes. A total of 77% of the
specimens were derived from autopsy and 23% from biopsy
specimens. Tissue was processed according to the guidelines
of the Swiss Society of Pathology. All cases were entirely
reviewed for histotype classification by two pathologists (S.T.
and A.S.). Clinical data were retrospectively assessed from
medical archives of the different hospitals and the local
cancer registries.
2.2. TMA construction and immunohistochemistry
A set of three tissue microarrays (TMA) with quadruple
punches per patient (total n = 1408) was accomplished with a
custom-made, semi-automatic tissue arrayer (Beecher
Instruments, Sun Prairie, WI, USA), as previously described
[10]. Sections (4.5-mm thick) of TMA blocks were transferred
to an adhesive-coated slide system (Instrumedics, Hack-
ensack, NJ, USA) supporting the cohesion of 0.6-mm array
elements on glass. De-paraffined sections were stained on
either a Ventana (Ventana Medical Systems, Tucson, AZ, USA)
or a Bond automat (Vision Biosystems, Melbourne, Australia),using the following primary antibodies: polyclonal rabbit
anti-periostin (1:500, clone OSF-2, Biovendor Laboratory
Medicine Inc., Modrice, Czech Republic), monoclonal anti-
PTEN (1:200, clone 6H2.1, Dako, Glostrup, Denmark),
monoclonal anti-EGFR (pre-diluted, clone 3C6, Ventana
Medical System Inc., Tucson, AZ, USA), polyclonal anti-ILK1
(1:50, clone RB1668, Abgent, San Diego, USA), monoclonal
anti-integrin b1 (1:800, clone 4B7R, Abcam, Cambridge, UK),
polyclonal anti-p21 (1:50, clone SC-397, SCBT, Santa Cruz,
CA, USA) and polyclonal anti-p27 (1:30, clone SC-528, SCBT,
Santa Cruz, CA, USA). Detection with respective secondary
antibodies was performed with Ultraview Amp (Ventana) or
Refine-DAB (Vision Biosystems).
2.3. Data interpretation and statistical analysis
The intensity level of immunoreactivity of the EMT
cascade proteins was scored semi-quantitatively: 0 (nega-
tive), 1 (weak), 2 (moderate) and 3 (strong) in stroma and
tumour cells, including the plasma membrane, cytoplasm
and nucleus as distinct compartments, by two observers
(A.Sc./A.So.). A mesothelioma-cell-associated signal was
considered if three or more cells were positive. A global sum
score was created from the four cores and was dichotomised
closest to the median into low and high. Clinical data were
retrospectively assessed as completely as possible from the
medical archives of different hospitals and the local cancer
registry. The material of the patients came mainly from
autopsies and there was no standardised therapy at this time
period. Associations and correlations with clinico-pathologic
parameters were examined by chi-squared and Kendall’s tau-
b tests, respectively, for both non-dichotomised as well as
dichotomised parameters. OS was calculated by the Kaplan—
Meier method and survival time differences were compared
using the log-rank test. Significant parameters were further
analysed by multivariate Cox proportional hazards regression
models to test for independency. All analyses were carried
out using the SPSS 16.0.1 software package (SPSS Inc.,
Chicago, IL, USA).
3. Results
3.1. Cohort description
The total cohort of 352 patients comprised 114 epithe-
lioid, 46 sarcomatoid and 192 biphasic histotypes. Further
clinical data could be retrieved from 206 of these 352
patients (59%), who were mainly males (94%). The median
age was 62 years. Asbestos exposure was known in 97 patients
(47%). Disease was located in 52% of the patients on the right,
36% on the left and 3% on both sides. As tumour stage was not
documentable in most cases, a retrospective staging was
performed for 102 patients, based on the surgical pathology
reports according to the IMIG staging system [11], stage T4
being predominant with 71%. Both regional and mediastinal
lymph nodes as well as distant metastases were present in
90% of the patients. Only 30% of the patients received
therapy, 70% were treatment-naı¨ve. Treatment was surgical
for 67 patients and comprised 26 extrapleural pneumonec-
tomies, 16 pleurectomies and 25 palliative procedures, such
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Table 1
Survival data for patients with available complete follow-up data (n = 128).
n = 128a % Univariate Multivariate
Med OS 95% CI p-value HR 95% CI p-value
Lower Upper Exp (B) Lower Upper
Age
<62 years 66 52 12.6 8.4 16.9
>62 years 62 48 10.9 6.7 15.2 0.029
Gender
Male 120 94 11.7 9.6 13.9
Female 8 6 11.6 8.1 15.2 0.077
Treatment
No 71 57 9.8 7.1 12.4
Any 54 43 14.2 9.5 18.9 0.002 0.644 0.433 0.957 0.029
Histotype
Epithelioid 38 30 12.7 8.4 17.0
Sarcomatoid 17 13 6.5 4.9 8.1
Biphasic 73 57 13 11.2 14.8 0.009
Periostin Stroma
Low 73 57 12.7 10.6 14.8
High 55 43 11.1 6.6 15.7 0.171
Periostin Tu-Cyto
Low 70 55 14 9.7 18.4
High 58 45 9.5 5.9 13.1 <0.001 1.824 1.249 2.665 0.002
EGFR Tu-Mem
Low 70 55 11.6 9.5 13.7
High 58 45 11.7 8.5 15.0 0.296
Integrin b1 Stroma
Low 69 54 10.7 9.2 12.3
High 58 46 13 12.1 14.0 0.109
Integrin b1 Tu-Mem
Low 65 51 11.7 8.9 14.5
High 62 49 11.5 8.5 14.5 0.902
ILK Tu-Cyto
Low 62 48 10.7 7.8 13.7
High 66 52 13.2 11.1 15.3 0.022
PTEN Tu-Cyto
Low 79 62 10.3 8.3 12.3
High 48 38 15.5 3.8 27.2 <0.001 0.560 0.367 0.854 0.007
p21 Tu-Nuc
Low 66 52 10.3 8.2 12.3
High 62 48 13.2 12.2 14.2 0.006
p27 Tu-Nuc
Low 62 49 10.7 8.3 13.1
High 65 51 13.2 12.1 14.3 0.023
Kaplan—Meier analysis with log rank test.
a Number of patients varying, dependent on achievable data, n = 127 for integrin b1 membrane and stroma, PTEN and p27, n = 125 for treatment.as talc pleurodesis or tumour debulking. A total of eight
patients received only chemotherapy in different combina-
tions, mostly platinum-based. Four patients received radia-
tion therapy. The median overall survival of the 128 patients
with complete follow-up data (Table 1) was 11.7 months (95%
confidence interval (CI): 10.0—13.6).
3.2. Protein expression patterns
In the extracellular matrix of the peritumoural stroma,
periostin and integrin b1 protein expressions were found in
99% of the tumours (any core with any positivity 1—3) in the
form of a fibrillary staining (Fig. 1). In the tumour cells,cytosolic expression of periostin was detectable in 96%, of
PTEN in 38% and of ILK in 49%. Plasma membrane expression
of EGFR was observed in 86%, of integrin b1 in 99%; nuclear
expression of p27 in 68% and of p21 in 47% of the tumours.
Table 2 shows the frequency distribution of protein expres-
sion intensities per individual core (0 = negative, 1 = weak,
2 = moderate and 3 = strong).
3.3. Correlation with clinico-pathologic parameters
An association of any marker expression and an asbestos
exposure could not be found in this retrospectively collected
data. Detailed histotype analyses per TMA core revealed that
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Fig. 1. Examples of EMT protein marker expression in a patient each with
epithelioid (left panel) and sarcomatoid (right panel) mesothelioma, respec-
tively (magnification 400): (A) tumour and stroma cells showing a variable
expression of periostin in both the epithelioid and sarcomatoid histotype. (B)
Membranous EGFR staining. (C) Integrin b1 in comparison to EGFR, also with
strong membranous expression. (D) Strong staining of ILK in the cytoplasm,
while nuclei remain unstained. (E) PTEN localised to the cytoplasm. (F) p21
presenting a variably strong nuclear expression. (G) p27 presenting a variably
strong nuclear expression.
Table 2
Frequency distribution of protein expression intensities (0 = no expression,
1 = low, 2 = moderate, 3 = strong) of the EMT markers per the individual cores
in percent.
0 (%) 1 (%) 2 (%) 3 (%)
Periostin Stro 3.6 26.6 22.1 47.7
Periostin Tu-Cyto 12.0 24.1 21.7 42.2
EGFR Tu-Mem 23.5 40.0 28.7 7.8
Integrin b1 Stro 3.0 32.1 38.8 26.1
Integrin b1 Tu-Mem 8.2 34.6 30.5 26.7
ILK Tu-Cyto 62.6 25.3 10.3 1.8
PTEN Tu-Cyto 69.5 13.4 6.3 10.7
p21 Tu-Nuc 70.6 25.4 3.6 0.4
p27 Tu-Nuc 44.5 43.2 9.3 3.0high expression of both stromal as well as cytoplasmic
periostin were associated with the sarcomatoid histotype. By
contrast, high membranous EGFR and integrin b1 as well as
high nuclear p27 levels were associated with the epithelioid
histotype. Correlation among markers showed that most of
them (EGFR, integrin b1, ILK, PTEN, p21 and p27) were
positively correlated with each other except periostin, which
also showed negative correlations. High expression of stromal
periostin was positively correlated with high stromal integrin
b1, but negatively with high EGFR, membranous integrin b1,
PTEN and p27 (Table 3).
3.4. Survival analysis
Univariate survival analysis revealed age, histotype and
therapy as OS prognosticators for the 128 patients with
complete follow-up data (Table 1). Further, high cytoplasmic
periostin was associated with decreased OS, whereas high
cytoplasmic PTEN and ILK and as well as high nuclear p21 and
p27 were inversely correlated with better OS. By contrast,the protein expression level of EGFR at the tumour cell
plasma membrane did not have significant survival impact.
All significant parameters of the univariate analysis were
introduced into a Cox proportional hazard ratio model in
order to test for independency (Table 1). Treatment (hazard
ratio (HR) 0.644; 95% CI: 0.433—0.957, p = 0.029) as well as
low cytoplasmic periostin (HR 1.824; 95% CI 1.249—2.665;
p = 0.002) and a high cytoplasmic PTEN (HR 0.560; 95% CI
0.367—0.854; p = 0.007) were maintained as independent
prognosticators for better overall survival (Fig. 2).
4. Discussion
In this large bank of formalin-fixed and paraffin-embedded
tissue of 352 MPM patients, mainly treatment-naive patients
were screened for the expression of different markers
belonging to a putative EMTaxis. Low expression of periostin
and high expression of PTEN in the tumour cell cytoplasm
were independent factors for better OS.
In this study, we focussed on the periostin—integrin axis
[12], which is known to cross talk with the EGFR pathway at
the plasma membrane level (Fig. 3). We could find an
association of high cytoplasmic periostin with the sarcoma-
toid histotype and with decreased OS; thus, assessment of
this protein might help identify the sarcomatoid histotype
[10]. It is well conceivable that both EMT of mesothelioma
cells as well as increased peritumoural fibrosis are important
factors for high invasiveness and chemoresistance of MPM,
respectively.
Oncogenic EGFR is overexpressed in many tumours,
including MPM [13], but without impact on survival [14].
Herein, the same result was found. Furthermore, clinical
studies have shown that treatment with tyrosine kinase
inhibitors had no impact on MPM patients’ survival. EGFR is
influenced by asbestos as shown in in vitro experiments and
leads to an activation of the Erk pathway acting on cell
survival and proliferation [14].
Integrin b1 is a transmembrane receptor not only for
extracellular matrix proteins such as fibronectin, laminin and
collagen, but also for periostin [15]. As a result of binding,
various cellular responses are observed, including alterations
in survival, proliferation, spreading and migration, gene
transcription and differentiation [16]. Downstream signalling
with cytoplasmic stabilisation of the cell cycle regulators p21
(WAF/CIP1) and p27 (KIP1) by Akt is modified by PTEN and ILK
[17]. Both markers correlated with longer survival in our
analysis, PTEN with even independent prognostic value,
underscoring its function as tumour suppressor. PTEN is
located underneath the plasmamembrane and has important
regulatory functions at this position on signal transduction
from the extracellular matrix to the tumour cell nucleus,
mainly by action on Akt [18,19]. Akt is assumed to be themost
important player in this axis and was proven to be involved in
proliferation of different tumours, including MPM. In vitro,
reduction ofmesothelioma cell proliferation andmotility was
achieved by targeting the PI3K/Akt pathway with PI3K
inhibitors [20]. Akt staining was performed with different
commercially available antibodies but was not reproducible,
so that the results were omitted from analysis. ILK is a protein
kinase inducing a range of signalling pathways after integrin
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Table 3
Correlation of EMT marker expression with histotype and among each other on individual cores (n = 1408).
Periostin EGFR Integrin b1 ILK PTEN p21 p27
Stroma Tu-Cyto Tu-Mem Stroma Tu-Mem Tu-Cyto Tu-Cyto Tu-Nuk Tu-Nuk
Individual
Histotype
Ep-Sa-Bi
tau 0.222 0.110 0.138 0.013 0.063 0.072 0.070 0.106 0.008
p <0.001 <0.001 <0.001 0.616 0.013 0.005 0.007 <0.001 0.754
Ep-Sa
tau 0.296 0.211 0.426 0.012 0.096 0.008 0.015 0.039 0.085
p <0.001 <0.001 <0.001 0.698 0.002 0.797 0.634 0.206 0.006
Periostin
Stroma
tau 0.539 0.105 0.112 0.126 0.011 0.070 0.036 0.008
p <0.001 <0.001 <0.001 <0.001 0.690 0.006 0.180 0.753
Tu-Cyto
tau 0.009 0.130 0.106 0.000 0.151 0.009 0.020
p 0.742 <0.001 <0.001 0.996 <0.001 0.727 0.453
EGFR
Tu-Mem
tau 0.076 0.315 0.176 0.169 0.191 0.270
p 0.004 <0.001 <0.001 <0.001 <0.001 <0.001
Integrin b1
Stroma
tau 0.189 0.038 0.105 0.117 0.124
p <0.001 0.151 <0.001 <0.001 <0.001
Tu-Mem
tau 0.069 0.079 0.197 0.218
p 0.010 0.002 <0.001 <0.001
ILK
Tu-Cyto
tau 0.414 0.321 0.346
p <0.001 <0.001 <0.001
PTEN
Tu-Cyto
tau 0.430 0.470
p <0.001 <0.001
p21
Tu-Nuk
tau 0.494
p <0.001
p27
Tu-Nuk
tau
p
Kendall’s tau-b test (tau = correlation coefficient, p = p-value).activation and was found to be overexpressed in MPM by
Watzka et al. [21], thereby correlating with higher patient’s
age. Herein, ILK was expressed in 49% of MPM with any
positivity, and had impact, although not independent, on OS.
The two cyclin-dependent kinase inhibitors p21 and p27
are downstream markers in the Akt pathway. Nuclear import
of p21 and p27 is thereby supposed to be increased, leading
to growth control. More recently, both proteins have been
implicated in EMT through transcription factors such as Snail
or Twist [22,23]. In MPM, high expression of p27 correlatedwith better patient’s survival [24], a finding which is
corroborated by our results, although without independent
prognostic value.
For better stratification of patients, precise prognostic
and diagnostic markers to select MPM patients who could
benefit from treatment are required. According to the
results of this study, patients with high cytoplasmic
periostin combined to decreased cytoplasmic PTEN may
be defined as high-risk group for poor prognosis. One of the
disadvantages of the study is the retrospective nature of
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Fig. 2. Overall survival with dichotomised cytoplasmic periostin expression.
Low expression (black curve, median overall survival 12.7 months (95% CI 9.7—
18.4 months)) and high expression (gray curve, median overall survival 9.5
months (95% CI 5.9—13.1)).
Fig. 3. Schematic picture of the proposed EMTaxis onto p21 and p27, triggered
by periostin.the clinical data. Therefore, correlation of protein marker
expression with tumour stage and therapy was limited. It is
planned to evaluate the prognostic impact of these markers
in selected patients who underwent standardised multi-
modality therapy, including neo-adjuvant platinum-based
chemotherapy, extrapleural pleuro-pneumonectomy and
radiotherapy [25].
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